These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25251901)

  • 21. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
    Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
    Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of an angiotensin-converting enzyme inhibitor improves vascular function and urinary albumin excretion in low-risk essential hypertensive patients receiving anti-hypertensive treatment with calcium channel blockers. Organ-protecting effects independent of anti-hypertensive effect.
    Watanabe Y; Takasugi E; Shitakura K; Okajima K; Hota N; Kubo Y; Nunoda S; Otsuka K
    Clin Exp Hypertens; 2011; 33(4):246-54. PubMed ID: 21699451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of renal denervation with a standard irrigated cardiac ablation catheter on blood pressure and renal function in patients with chronic kidney disease and resistant hypertension.
    Kiuchi MG; Maia GL; de Queiroz Carreira MA; Kiuchi T; Chen S; Andrea BR; Graciano ML; Lugon JR
    Eur Heart J; 2013 Jul; 34(28):2114-21. PubMed ID: 23786861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.
    Siewert-Delle A; Ljungman S; Hartford M; Wikstrand J
    Am J Hypertens; 1995 Feb; 8(2):113-23. PubMed ID: 7755939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
    Petrie JR; Marso SP; Bain SC; Franek E; Jacob S; Masmiquel L; Leiter LA; Haluzik M; Satman I; Omar M; Shestakova M; Van Gaal L; Mann JF; Baeres FM; Zinman B; Poulter NR;
    J Hypertens; 2016 Jun; 34(6):1140-50. PubMed ID: 26855018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.
    Nielsen R; Jorsal A; Tougaard RS; Rasmussen JJ; Schou M; Videbaek L; Gustafsson I; Faber J; Flyvbjerg A; Wiggers H; Tarnow L; Kistorp C
    Diabetes Obes Metab; 2020 Nov; 22(11):2141-2150. PubMed ID: 32627271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats.
    Zhou X; Huang CH; Lao J; Pocai A; Forrest G; Price O; Roy S; Kelley DE; Sullivan KA; Forrest MJ
    Cardiovasc Diabetol; 2015 Mar; 14():29. PubMed ID: 25888997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.
    Kramer CK; Zinman B; Choi H; Connelly PW; Retnakaran R
    J Clin Endocrinol Metab; 2015 Oct; 100(10):3702-9. PubMed ID: 26230296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria.
    Jerums G; Allen TJ; Campbell DJ; Cooper ME; Gilbert RE; Hammond JJ; O'Brien RC; Raffaele J; Tsalamandris C;
    Diabet Med; 2004 Nov; 21(11):1192-9. PubMed ID: 15498085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High salt intake promotes a decline in renal function in hypertensive patients: a 10-year observational study.
    Ohta Y; Tsuchihashi T; Kiyohara K; Oniki H
    Hypertens Res; 2013 Feb; 36(2):172-6. PubMed ID: 23051657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis.
    Mann JFE; Buse JB; Idorn T; Leiter LA; Pratley RE; Rasmussen S; Vilsbøll T; Wolthers B; Perkovic V
    Diabetes Obes Metab; 2021 Sep; 23(9):2058-2066. PubMed ID: 34009708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of hyperuricemia on the blood pressure response to antihypertensive agents in hospitalized elderly patients.
    Zhu P; Lin F; Lin C; Hong D; Lin K; Chen H
    J Cardiovasc Med (Hagerstown); 2012 Nov; 13(11):741-6. PubMed ID: 22964647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Greater reduction of urinary albumin excretion in hypertensive patients with perindopril than nifedipine].
    Lin J; Chen D; Wu K
    Zhonghua Nei Ke Za Zhi; 1999 May; 38(5):299-301. PubMed ID: 11798658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
    Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
    Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
    Ohishi M; Takagi T; Ito N; Tatara Y; Hayashi N; Shiota A; Iwamoto Y; Katsuya T; Rakugi H; Ogihara T
    Hypertens Res; 2007 Dec; 30(12):1187-92. PubMed ID: 18344623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of 14 years of antihypertensive treatment on renal function and urinary albumin excretion in primary hypertension.
    Siewert-Delle A; Ljungman S; Hartford M; Wikstrand J
    Am J Hypertens; 1996 Sep; 9(9):841-9. PubMed ID: 8879339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.